A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
This is an early-stage study testing a new drug called INCA036873 in people with advanced cancer, including solid tumors and blood cancers. Researchers will monitor your safety and how well your body tolerates the medication as they determine the right dose.
Key Objective:This trial is testing whether INCA036873 can be safely used to treat advanced cancers that have not responded to standard treatments.
Who to Consider:People with advanced solid tumors or blood cancers who have exhausted standard treatment options may want to consider enrolling in this study.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years. * ECOG performance status of 0 or 1. * Histologically confirmed: * Clear cell renal cell carcinoma (ccRCC). * Diffuse large B-cell lymphoma (DLBCL, NOS). * High-grade B-cell lymphoma (HGBCL). * Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL). * Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement). * Disease progression, relapse, or refractory to prior therapy: * ccRCC: ≥1 prior line incl. ICI + TKI. * DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage. * PTCL/CTCL: ≥1 prior systemic therapy. * Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL). * Tumor tissue available for central testing. Exclusion Criteria: * Untreated or progressive CNS disease unless previously treated and stable. * Other active invasive malignancy within 2 years (except certain low-risk cancers). * Prior CD70-targeting therapy, including CAR T. * ASCT or CAR T ≤12 weeks before en